Preparing for and Managing Rare Diseases

SEP. 8-10, 2020 | VIRTUAL
We live in an age of advancement. Think of the natural language processing and robotics innovations necessary to power your Alexa (or Google or Siri). Likewise, this also is an age of complexity. We are constantly being driven to find new solutions to new problems. In managed care pharmacy, we strive to ensure patients have access to medicines they need at a cost they can afford. That puts us at the critical crossroads between advancement and complexity.

During this AMCP Partnership Forum, we will examine one aspect of that managed care crossroads: preparing for and managing rare diseases. New therapies create new hope, but they often come with million-dollar price tags. During our time together, we will discuss how managed care organizations—charged with evaluating evidence, providing access, and managing outcomes—can effectively serve these small but important patient populations.

To have a successful dialogue, I am pleased to welcome a variety of participants, including payers, pharmacies, integrated delivery system leaders, health economics and outcomes research analysts, academicians, providers, pharmaceutical manufacturers, and other health care stakeholders.

Thank you for your participation. Together, we will:

1. Identify key barriers by stakeholder around access and coverage for rare disease therapies and propose strategies to address identified barriers.
2. Develop recommendations on how to manage one-time versus longer-term therapies in managed care settings.
3. Collect examples of early adopters and lessons learned that key stakeholders may apply to creating benefits for rare disease therapies.

The AMCP Partnership Forum would not be possible without the generous support of our sponsors: AstraZeneca, Dicerna, Genentech, National Pharmaceutical Council, Novo Nordisk, Pfizer, Precision Value, Sanofi, Sarepta, Seattle Genetics, Spark Therapeutics, and Takeda.

Following this event, AMCP will produce proceedings documenting the forum’s findings and recommendations in an upcoming issue of AMCP’s Journal of Managed Care & Specialty Pharmacy, which is widely disseminated to decision makers around the country.

I look forward to a fruitful AMCP Partnership Forum.

Sincerely,

Susan A. Cantrell, RPh, CAE
AMCP CEO
Jeff Lee, PharmD, FCCP
Associate Dean for Academic Affairs
Lipscomb University College of Pharmacy

Jeff Lee, PharmD, FCCP, is associate dean for academic affairs at Lipscomb University College of Pharmacy in Nashville. Jeff joined Lipscomb in 2013 after 20+ years in the pharmaceutical industry focused in pharmacoeconomic and health outcomes research. He is active in numerous national pharmacy associations and was chair of AMCP’s Format Executive Committee from 2015–2018, leading a group of national payer, industry, and academic experts on all matters related to the AMCP Format for Formulary Submissions. He led development of fellowship training guidelines in pharmacoeconomics for the American College of Clinical Pharmacy and was elected as an ACCP Fellow in 2003.
PREPARING FOR AND MANAGING RARE DISEASES

AGENDA

TUESDAY, SEP. 8

1:30-3pm ET Welcome and agenda
Presentation: Summary of pre-forum survey results.

WEDNESDAY, SEP. 9

Noon-1:30pm ET Presentation and panel discussion: Challenges in managing and providing timely access to rare disease therapies.

2pm ET Breakout session 1: Moderator-led small group discussions with polling. Identify challenges and barriers by stakeholder around coverage for rare disease therapies.

2-2:50pm ET Group 1 Group 2

3-3:50pm ET Group 3 Group 4

4-5pm ET Discussion: Moderator-led report outs and discussion.

HOSTED BY AMCP IN PARTNERSHIP WITH

AstraZeneca  Dicerna  Genentech  National Pharmaceutical Council

Pfizer  PRECISIONvalue  SANOF

SAREPTA Therapeutics  Seattle Genetics  Spark Therapeutics  Takeda
THURSDAY, SEP. 10

Noon-1:30pm ET  Welcome back day 1 debrief  
Panel: Opportunities in managing and providing timely access to rare disease therapies.

2pm ET  Breakout session 2: Moderator-led small group discussions with polling. Strategies to address identified barriers by stakeholder.

2-2:50pm ET  Group 1  Group 2

3-3:50pm ET  Group 3  Group 4

4-5pm ET  Discussion: Moderator-led report outs and summary.  
Next steps and close
**PREPARING FOR AND MANAGING RARE DISEASES**

**PARTICIPANTS**

**Angela Banks**  
Vice President, External Affairs  
UnitedHealth Group

Angela Banks, vice president, external Affairs at UnitedHealth Group, is a leader in the pharmaceutical and health care industries specializing in health policy, patient advocacy, and market access. Angela is responsible for leading the strategic approach to prescription drug and pharmacy care services policy. Angela is known for effectively collaborating with pharmaceutical industry executives, regulators, and other payers to address barriers to access and affordability as well as finding innovative approaches to ensuring high quality care and improved health outcomes.

**Diane Berry, PhD**  
Senior Vice President, Global Health Policy, Government and Patient Affairs  
Sarepta Therapeutics

Diane Berry, PhD, is a senior vice president in global policy, government and patient affairs for Sarepta Therapeutics. She engages policymakers at the federal, state, and local levels, as well as patient advocacy organizations, to advance critical policies related to newborn screening, regulatory policy, and reimbursement and access with a goal of expediting development and patient access to genetic-based therapies for rare diseases. Previously, Dr. Berry served as a subcommittee staff director and senior professional staff member for the U.S. House of Representatives Committee on Homeland Security and as chief scientist and senior biodefense advisor at the Department of Homeland Security in the Office of Health Affairs. Dr. Berry was a senior science advisor at McKenna, Long, and Aldridge and a science and technology policy advisor and fellow within the Department of Defense through the American Association for the Advancement of Science.

**Justin Bioc, PharmD, BCPS, BCGP**  
Clinical Pharmacist  
Devoted Health Inc.

Justin Bioc, PharmD, BCPS, BCGP, is the inaugural clinical pharmacist at Devoted Health where he leads the strategic development and execution of clinical programs that drive optimal quality ratings, lower unnecessary health utilization, and ensure high quality care. He has experience in running outpatient community pharmacies, academia, medical, and pharmacy utilization management; case and chronic disease management; value-based care delivery, technology; and health care innovation/disruption. Dr. Bioc obtained his Bachelor of Science and Doctor of Pharmacy from Northeastern University.
Lisa Cashman, PharmD
Vice President, Specialty Solutions
MedImpact Healthcare Systems LLC

Lisa Cashman, PharmD, has 20 plus years of health care experience, including pharmacy benefit management and understanding client goals across Medicare Part D, commercial insurance, Medicaid, and health insurance exchange. Her clinical program management team consults clients on formulary, utilization management, clinical intervention programs, and drug spend and trend management. Previously, she was responsible for MedImpact formulary management strategy and execution ensuring clinical appropriateness, optimal financial performance, reporting, regulatory compliance, specialty drug management, and drug information and data. She received a Bachelor of Arts from the University of California (UC), San Diego, and a Doctor of Pharmacy from UC, San Francisco. She completed a general residency at the VA Medical Center Department of Medicine in Palo Alto, Calif. She’s an AMCP member and serves on the AMCP Executive Format Committee.

James Chambers, PhD, MPharm, MSc
Associate Professor
Tufts Medical Center

James Chambers, PhD, MPharm, MSc, is an investigator at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, and an associate professor of medicine at Tufts University School of Medicine. His research has highlighted variation in patients’ access to specialty and orphan medications and in the evidence base that health plans cite in their policies. He graduated from Queens University in Belfast with a Master of Pharmacy degree and previously worked as a pharmacist in the U.K. and Ireland. Dr. Chambers also obtained an Master of Science from the University of York and Doctor of Philosophy from Brunel University, both in health economics.

Michael Ciarametaro, MBA
Vice President of Research
National Pharmaceutical Council

Michael Ciarametaro, MBA, serves as the National Pharmaceutical Council’s vice president of research. In this position, he plays a key role in developing and delivering NPC’s portfolio of health policy and health outcomes projects. Michael has 13 years of health care industry experience with both pharmaceutical manufacturers and payers. Most recently, he was a senior research manager at Evidera, where he designed and led a wide variety of both qualitative and quantitative studies across multiple health care industries and stakeholders. His work analyzed reimbursement and treatment patterns for drugs, biologicals, and devices. Prior to Evidera, he served as a financial analysis manager at WellPoint NextRx and as lead staff at Noblis, a nonprofit science, technology, and strategy organization. Mr. Ciarametaro holds a Bachelor of Science from the University of Virginia and received his Master of Business Administration from George Mason University.
Participants

Jennifer Day, PharmD
Coordinator, Emerging Therapeutics Strategy Program
Kaiser Permanente

Jennifer Day, PharmD, is coordinator of the emerging therapeutics strategy program, which is part of drug intelligence and strategy, for Kaiser Permanente National Pharmacy. Dr. Day’s areas of expertise include drug information and analysis of clinical trial evidence; development of evidence-based guidelines; strategic planning for the use of biologics and emerging pharmaceuticals, including gene therapies and biosimilars; and pharmaceutical pipeline forecasting. She plays a key role in facilitating the development of innovative treatment pathways through collaboration with physicians and pharmacists in the various Kaiser Permanente regions to proactively evaluate and prepare for optimal use of new and pipeline emerging therapies.

Stanley Ferrell, RPh, MSPPharm, MBA
Associate Director, Managed Markets
Seattle Genetics

Stanley (Stan) Ferrell, RPh, MSPPharm, MBA, is the associate director, clinical services for Seattle Genetics. He is responsible for regional business development and market access with managed markets payers. He has worked for biopharmaceutical organizations and PBMs in medical affairs, sales, marketing, pricing, and contracting, and is knowledgeable in the value assessment of new therapeutics to the marketplace. He has helped health plan and employers improve patient care, control pharmacy trend, and identify strategies to manage overall health care costs. Stan has Bachelor of Science degrees in Zoology and Pharmacy, a Master of Business Administration, and a Master of Science in Pharmacy with a concentration in Applied Pharmacoeconomics and Policy. He is a licensed pharmacist in North Carolina. An active member with AMCP, Stan has served on the board of directors and chaired various committees. He works with the award-winning AMCP Student Chapter at the University of North Carolina Eshelman School of Pharmacy where he is a frequent guest lecturer.

Denise Giambalvo, MS
Vice President
Midwest Business Group on Health

Denise Giambalvo, MS, is vice president of Midwest Business Group on Health (MBGH) and leads various sponsor and grant-funded projects, including the National Employer Initiative on Specialty Drugs. Prior to joining MBGH, Denise served as the executive director for Employers’ Heath Coalition (EHC) in Fort Smith, Ark. In this role, she was directly involved in contract negotiations for the PBM, Employers’ Choice Rx. Committed to carrying out the Coalition’s mission to “...enhance the general health of the community;” Denise oversaw EHC’s launch of the National Diabetes Prevention Program and negotiated a discounted group rate for employer-sponsored financial well-being programs. Denise has been a team-collaborator with stakeholders on research and pilot programs including limited-fill, site-of-service, mental and behavioral health, and data analysis. She currently serves on the Management and Implementation Committee for the Institute of Medicine Chicago.
Neil Goldfarb
President and CEO
Greater Philadelphia Business Coalition on Health

Neil Goldfarb is founding president and CEO of the Greater Philadelphia Business Coalition (GPBCH) on Health, which helps employers improve population health and health care quality and value. Established in 2012, GPBCH represents over 1.6 million covered lives. Neil has 40+ years research and management experience and more than 60 peer-reviewed articles. Previous positions include associate dean, Jefferson College of Population Health; director of ambulatory care performance improvement, Thomas Jefferson University; and vice president of health services for Philadelphia’s first Medicaid managed care plan. He is a member of the board of the National Alliance of Healthcare Purchaser Coalitions.

Karl Gregor, PharmD, MS
Vice President and Practice Leader, Pharmacy Advisory Services
Optum

Karl Gregor leads the pharmacy advisory services at Optum and has 27 years of PBM, pharmaceutical industry, and consulting experience across the pharmacy ecosystem. He was previously the practice leader for Optum’s access and value solutions group, which focused on European and North American reimbursement assessments and solutions for a wide variety of pharmaceutical, device, and diagnostic products. Prior to Optum, Karl held U.S., European, and Global HEOR leadership and research roles at Eli Lilly and Company and PCS Health Systems.

Chris Guinther, PharmD, RPh
System Director, Pharmacy Benefits
Bon Secours Mercy Health

Chris Guinther, PharmD, RPh, is a registered pharmacist with 20 years experience in community pharmacy, clinical sales including pharmacy benefit management, specialty, infusion, and 340b. He provides consulting services to reduce pharmacy cost and enhance insurer-provider relations. Dr. Guinther also provides continuing pharmacy education to pharmacists and pharmacy technicians nationally. He works with the Joint Commission to discuss standards and measures for medication reconciliation in academic hospitals. His specialties are infertility, oncology, hepatitis C, organ transplant, and multiple sclerosis.
**PARTICIPANTS**

**Matt Harman, PharmD, MPH**  
Senior Director of Pharmacy  
Employers Health

As senior director of pharmacy, Matt Harman, PharmD, MPH, monitors, evaluates and improves the pharmacy plan performance of the Employers Health $1 billion PBM group purchasing programs with CVS and OptumRx. He works proactively with the organization’s more than 215 member employers to provide clinical information and strategies to help reduce health care spend and positively influence the health of more than 3 million individuals. Dr. Harman founded the Employers Health managed care pharmacy residency program and currently serves as the director. He obtained his Doctor of Pharmacy and Master of Public Health at the University of Kentucky prior to his residency at The Ohio State University Health Plan.

**Dorothy Hoffman**  
Access Innovation Lead  
Pfizer

Dorothy Hoffman is the access innovation lead within PHI's Healthcare Innovation Center. The Healthcare Innovation Center has responsibility for co-creating novel market access and prescription drug reimbursement solutions for products across Pfizer's biopharmaceutical group. Solutions include value-based care models, financing and affordability solutions, and social determinants of health. Prior to joining Pfizer, Dorothy was vice president of prescription drug policy at UnitedHealth Group. Dorothy's team was responsible for implementing the company's pharmacy care services transformation and growth initiative with federal health programs utilizing newly acquired OptumRx specialty pharmacy, digital pharmacy, and behavioral health assets.

**Thomas Hubbard, MPP**  
Vice President of Policy Research  
NEHI – Network for Excellence in Health Innovation

NEHI is a nonprofit health policy organization with a mission to advance innovations that improve health and achieve greater value. Tom Hubbard manages NEHI projects on pharmaceutical value-based arrangements, medication management, medication adherence, comparative effectiveness research, and the use of real-world evidence. Tom previously served as vice president of the Massachusetts Technology Collaborative, and as an economic development aide to U.S. Senator John Kerry and Massachusetts Governor Michael Dukakis. He is a graduate of Harvard College and Harvard’s Kennedy School of Government.
**PARTICIPANTS**

**Paul Jeffrey, PharmD**  
Director of Pharmacy, Office of Clinical Affairs  
MassHealth/University of Massachusetts Medical School

Dr. Paul Jeffrey, PharmD, is the director of pharmacy for MassHealth. He is responsible for the pharmacy benefit for 1 million of MassHealth’s 1.85 million members and coordinating pharmacy clinical and business relations with the state’s Medicaid managed care plans. Dr. Jeffrey is also the associate professor of family medicine and community health at the University of Massachusetts Medical School. He received his undergraduate pharmacy degree from Massachusetts College of Pharmacy and his doctor of pharmacy from Duquesne University, completing a residency in hospital pharmacy at Mercy Hospital, Pittsburgh. Dr. Jeffrey currently serves as the president-elect of AMCP. He has contributed many presentations and publications to the field of pharmacy practice.

**Jacob Jolly, PharmD**  
Principal Consultant  
Blue Fin Group

With significant experience in specialty, retail, and hospital pharmacy, Jacob Jolly, PharmD, has held roles ranging from the front lines of patient care to leadership and business development. He has a thorough understanding of the health system pharmacy setting and brings a patient-centered approach to solving access challenges. Prior to his current role as principal consultant at Blue Fin Group, Dr. Jolly served as the director of strategy and market access for the specialty pharmacy program at Vanderbilt University Medical Center, where he developed the overarching strategic direction for all specialty pharmacy related activities. Dr. Jolly completed his pre-pharmacy coursework at Louisiana State University and received his Doctor of Pharmacy degree from Mercer University College of Pharmacy and Health Sciences.

**Gbolahan Jonathan**  
Senior Manager, Access Strategy (Koselugo)  
AstraZeneca

Gbolahan Jonathan is a pharmacist and a patient-focused professional that has been in the pharmaceutical industry for 13 years. He has been with AstraZeneca for 5 years where 4 of those years were spent on the access services team. He recently moved to the access strategy team in 2019 as a senior manager and strategy lead to support the launch of Koselugo.
PARTICIPANTS

Annie Kennedy
Chief of Policy and Advocacy
EveryLife Foundation for Rare Diseases

Annie Kennedy builds strong partnerships with policy makers, federal agencies, industry, and alliances. She currently leads the national Burden of Rare Disease Study, 21st Century Cures Act and PDUFA VII engagement, national newborn screening program engagement and state RUSP alignment legislation and innovating around therapy valuation and access issues. Annie has rare nearly three decades in rare diseases through her roles with Parent Project Muscular Dystrophy and the Muscular Dystrophy Association. She helped lead legislative efforts around passage and implementation of the MD-CARE Act (2001, 2008, 2014); the Patient-Focused Impact Assessment Act (PFIA), which became the Patient Experience Data provision within the 21st Century Cures Act (sec 3001); engagement with the FDA and industry around regulatory policy and therapeutic pipelines; led access efforts as the first therapies were approved in Duchenne; and engaged with ICER around the development of the modified framework for the valuation of ultra-rare diseases.

Michael Kobernick, MD, MS-HSA, MS-Pop Health, FAAFP, CPE
Senior Medical Director
Blue Cross of Michigan

Michael Kobernick, MD, MS-HSA, MS-Pop Health, FAAFP, CPE, the medical director of clinical account management for Blue Cross of Michigan. He has clinical oversight of the Care Management and well-being programs. In addition, Dr. Kobernick is lecturer at Jefferson College of Population Health and an adjunct professor in the Madonna University Public Health graduate program.

Troy Koch, PharmD, MBA
Director, Account Medical Lead
Takeda Pharmaceuticals

Troy Koch, PharmD, MBA, is currently a director, account medical lead for Takeda Pharmaceuticals. He engages in scientific exchange regarding Takeda products with some of the top corporate and national health plan and pharmacy benefits managers. Dr. Koch has an extensive career in the pharmaceutical and managed care industries, holding positions previously with Humana, Medimpact, and Hobart Core (now Precision for Value). He earned a Doctor of Pharmacy degree from the University of Kentucky, a Master of Business Administration from the University of Louisville, and completed a residency in managed care pharmacy with Humana Inc.
**Participants**

**Yuqian Liu, PharmD**  
Director, Specialty Clinical Solutions  
Magellan Rx Management  

YuQian Liu, PharmD, RPh, is a director of specialty clinical solutions with Magellan Rx Management. She is responsible for leading strategic initiatives for regional and national health plan clients and prospects in the management of specialty pharmacy utilization, as well as quality improvement. Dr. Liu also supports clinical program development, specialty drug landscape and pipeline analysis, and various clinical initiatives involving rare disease treatments. Additionally, Dr. Liu serves as a preceptor for APPE rotation students from Massachusetts College of Pharmacy and Health Sciences and the Western New England University, and is a member of the AMCP schools of pharmacy relations committee. She graduated with a Doctor of Pharmacy and a minor in pharmaceutical business from Philadelphia College of Pharmacy. Dr. Liu completed a PGY1 managed care pharmacy residency with Horizon Blue Cross Blue Shield of New Jersey.

**Mandy Leonard, PharmD, BCPS**  
System Director, Drug Use Policy and Formulary Management  
Cleveland Clinic  

Mandy Leonard, BS, PharmD, BCPS, earned her Bachelor of Science in pharmacy and Doctor of Pharmacy from Duquesne University in Pittsburgh. She completed a drug information practice residency at the Medical University of South Carolina. For the past 22 years, Dr. Leonard has overseen the department of pharmacy drug information service at the Cleveland Clinic Health System. She is an assistant professor at the Cleveland Clinic Lerner College of Medicine and is the pharmacology thread director. Dr. Leonard is also responsible for coordinating all Cleveland Clinic pharmacy residency programs including PGY1s, pharmacotherapy and health system pharmacy administration and leadership, and PGY2s. She has served as an ASHP residency guest surveyor for the past five years. Finally, she is responsible for drug shortages, drug recalls, REMS programs, and formulary management for the Cleveland Clinic Health System.

**Tom Koenig**  
VP Global Market Access  
Dicerna Pharmaceuticals  

Tom Koenig has over 30 years of experience in the pharma/biotech industry, with 20 of those years in market access roles. For the last 12+ years he has focused on specialty and specialty biologic products, having successfully launched multiple orphan drugs in that time. In his current role, he leads the build out of the market access capabilities for Dicerna, an emerging commercial stage biopharma company with expertise in RNAi therapeutics.
Erin Lopata, PharmD, MPH
Senior Director
Precision Value

Erin Lopata, PharmD, MPH, is a senior director on the access experience team with Precision Value, where she supports life science companies to optimize their market access strategy. Prior to joining Precision, Dr. Lopata spent more than 10 years with UPMC Health Plan, where she led specialty pharmacy strategy and commercial formulary development. She is an adjunct professor at the University of Pittsburgh School of Pharmacy. Erin received her Doctor of Pharmacy from the University of Pittsburgh School of Pharmacy, and her Master of Public Health from the University of Pittsburgh Graduate School of Public Health.

Jay Newman
General Manager, U.S. Commercial
Spark Therapeutics

Jay Newman has more than 30 years of commercial experience in the pharmaceutical and biotech industries and currently leads Spark Therapeutics US Commercial’s business. He envisioned, developed, and directed the execution of the organization’s innovative delivery model — SPARK PATHSM in support of LUXTURNA™, the first-ever gene therapy product therapy in the United States. SPARK PATH aims to advance patient access to care while balancing stakeholders’ needs involved in the care-delivery continuum. Previously, Jay led Biogen’s payer and channel marketing team, including multiple sclerosis, hemophilia, and rare disease. Jay also spent 24 years at Allergan in roles of increasing responsibility in market access and sales leadership, including leading the development of the market access team from a traditional pharmaceutical focus to having full responsibility of the Allergan corporate portfolio, including medical injectable products and devices. Before Allergan, Jay spent five years in the U.S. Army, achieving the rank of Captain.

Amy Niles
Executive Vice President
Patient Access Network (PAN) Foundation

Amy Niles oversees PAN Foundation’s relations and partnerships with the patient advocacy community and leads its public policy and advocacy initiatives. Before joining the PAN Foundation, Amy served for eight years as chair, medical relations and advocacy for the Together Rx Access program. Prior, she was president and CEO of the National Women’s Health Resource Center, now known as Healthy Women, for more than a decade. Amy has a master of business administration from Baruch College, City University of New York, and an undergraduate degree in biology from the University of Rochester.
**Participants**

**Heather Odem, PharmD**
Pharmacy Director, Government Programs Mississippi
UnitedHealthcare

Heather Odem, PharmD, is the director of pharmacy for UnitedHealthcare government programs in Mississippi. She is responsible for pharmacy financial and utilization trend monitoring and management, interfacing with state and other regulatory bodies, and managing relationships with OptumRx. Heather has more than 10 years of experience in the pharmacy industry. Her background includes district management in the retail pharmacy setting as well managed care. Heather holds a Bachelor of Science in Pharmacology from the University of California Santa Barbara, and a Doctor of Pharmacy from University of the Pacific in California. Heather is a registered pharmacist, licensed in California and Mississippi.

**Elisabeth M. Oehrlein, PhD, MS**
Senior Director, Research & Programs National Health Council

Elisabeth M. Oehrlein, PhD, MS, is the senior director of research and programs at the National Health Council, joining the organization in July 2018. Dr. Oehrlein crafts the NHC’s annual research and programmatic agenda in service to its mission and leads the NHC’s research and programmatic work on value, real-world evidence, and patient engagement. She is a mixed-methods researcher with expertise in epidemiologic, qualitative, and patient engagement methods, as well as patient focused medical product development. Dr. Oehrlein holds a bachelor of art degree from Franklin & Marshall College, a master of science degree in epidemiology from the University of Maryland School of Medicine’s Department of Epidemiology and Human Genetics, and a PhD in pharmaceutical health services research with a concentration in comparative effectiveness research/patient-centered outcomes research from the University of Maryland School of Pharmacy. She is an active member of the International Society for Pharmacoeconomics and Outcomes Research and holds leadership roles in the Patient-Centered and Real-World Evidence Special Interest Groups.

**Jignesh Patel, PharmD**
Medical Account Director
Novo Nordisk

Jignesh Patel is a 20-year industry medical professional who previously worked in the clinical setting as a pharmacist with experiences in a variety of therapeutic areas. Jignesh most recently worked in the BioPharm division of Novo Nordisk in hemophilia and other rare bleeding and growth hormone disorders. For the past 10 years, he has served in the managed markets area and helped pave understanding and guide formulary considerations in both of these therapeutic areas across the market access channel. He currently resides in Sugar Land, Texas with his wife and two young boys, where he likes to enjoy music, sports, and spending time with his boys.
PARTICIPANTS

Kasey Raetz, PharmD
Senior Director, Medical Pharma Contracting & Strategy
Express Scripts

Kasey Raetz, PharmD, is responsible for leading medical pharma contracting and strategy on behalf of Express Scripts’ combined enterprise. Prior to her current role, Dr. Raetz led the strategy and development of various Express Scripts’ clinical and value-based solutions, including the SafeGuardRx platform. Most recently, Dr. Raetz served as the director, value-based solutions. Dr. Raetz graduated from Southern Illinois University-Edwardsville School of Pharmacy with her doctorate in pharmacy. Prior to pharmacy school, Dr. Raetz graduated from the University of Missouri-Columbia with a Bachelor of Science in chemistry.

Will Richmond
Head, U.S. Value and Access Rare Disease/Rare Blood Disorders
Sanofi Genzyme

Will Richmond is head of U.S. value and access rare disease/rare blood disorders at Sanofi Genzyme. Committed to rare diseases, over the past 10+ years, he has worked in various roles to improve diagnosis rates, increase awareness, and secure access to treatments for orphan diseases. Will holds Master of Business Administration from Cornell University.

Mark Trusheim
Strategic Director
MIT NEWDIGS

Mark Trusheim is a strategic director at MIT NEWDIGS where he also co-leads the financing and reimbursement of Cures in the US (FoCUS) Project. He is also a visiting scientist at the MIT Sloan School of Management. Mark’s research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials, biosimilars, and digital health advances.
Katherine (Kat) Wolf Khachatourian, PharmD, MBA, is the chief quality and innovation officer for Physicians of Southwest Washington (PSW), an independent physician association administering Medicare Advantage, NextGeneration ACO, Bundled Payment Care Initiative programs, and supports commercial and Medicaid services contracts. Dr. Wolf develops clinical quality initiatives for medical, pharmacy, and risk programs, strategy deployment, and delegated functions for contracts served by her organization touching approximately 100,000 lives. Additionally, PSW is minority-owned by Multicare Health System (MHS), where Dr. Wolf works as a clinical executive sponsor of the MHS employee health plan, which provides self-funded coverage to 24,000 lives.

Thank You
To our distinguished participants and guests.

About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, and professionals in life sciences and biopharmaceutical companies leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management, and help patients access cost-effective and safe medications and other therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models.

AMCP Mission
To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies.
AMCP STAFF AND CONSULTANTS

Susan A. Cantrell, RPh, CAE  
Chief Executive Officer

Phil Bongiorno  
Vice President, Policy & Government Relations

Irene Chung  
Managed Care Research and Nonprofit Leadership Intern, AMCP Foundation

Liz Colangelo  
Senior Manager, Business Strategies

Lissette Cohen  
Coordinator, Marketing & Communications

Vyishali Dharbhamalla, PharmD  
Manager, Professional Affairs

Paula Eichenbrenner,  
MBA, CAE  
Executive Director, AMCP Foundation

Bridget Flavin  
Writer

Abigail Fredenburg, MA  
Director, Integrated Marketing & Communications

Julian Greer, CMP  
Senior Manager, Meetings & Forums

Nicholas Ladikos, PharmD,  
BCPS, BCGP, BCIDP  
Director of Professional Affairs

Matt Lowe  
Vice President, Business Strategies

Noreen Matthews, BSN, MBA  
Senior Consultant, Business Strategies

Cynthia Reilly, MS, BS Pharm  
Chief Operating Officer

Terry Richardson,  
PharmD, BCACP  
Senior Pharmacist Consultant

Ruby Singh, PharmD, BCPS  
Vice President, Education & Training
Findings and recommendations from this event will be published in an upcoming issue of AMCP’s Journal of Managed Care & Specialty Pharmacy and will be widely disseminated to decision makers around the country.